Lv6
2230 积分 2023-06-14 加入
Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
1个月前
已完结
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
1个月前
已完结
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors
1个月前
已完结
FGTI-2734 Inhibits ERK Reactivation to Overcome Sotorasib Resistance in KRAS G12C Lung Cancer
1个月前
已完结
KRAS inhibitors in drug resistance and potential for combination therapy
1个月前
已完结
Discovery of INCB159020, an Orally Bioavailable KRAS G12D Inhibitor
1个月前
已完结
“Undruggable KRAS”: druggable after all
1个月前
已完结
Clinical Perspectives to Overcome Acquired Resistance to Anti–Programmed Death-1 and Anti–Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer
3个月前
已关闭
Failure of Immunotherapy—The Molecular and Immunological Origin of Immunotherapy Resistance in Lung Cancer
3个月前
已完结
New insights into non-small cell lung cancer bone metastasis: mechanisms and therapies
3个月前
已完结
皖公网安备34019202002308
